-
Mashup Score: 1New long-term data show SHINGRIX continues to provide high protection against shingles in adults aged 50 and over for more than a decade | GSK US - 1 month(s) ago
End-of-trial data show 79.7% efficacy in participants aged 50 years and over, six to 11 years after vaccination
Source: us.gsk.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 5GSK announces cap of $35 per month on U.S. patient out-of-pocket costs for its entire portfolio of asthma and COPD inhalers | GSK US - 2 month(s) ago
GSK is taking this action as part of its longstanding commitment to improving access to respiratory medicines in the U.S.
Source: us.gsk.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 3Media | GSK - 6 month(s) ago
Latest press releases, media assets and global media contacts
Source: www.gsk.comCategories: General Medicine News, PayerTweet
News for #media and #investors: Today, we announced new positive long-term follow-up trial data for shingles. Find out more: https://t.co/UpvSBAnq9T https://t.co/z7m3NJi7BE